22157-91-1

Basic information

• Product Name: 1,3-bis(hydroxymethyl)-5-tert-butylbenzene
• Synonyms: 1,3-bis(hydroxymethyl)-5-tert-butylbenzene
• CAS NO: 22157-91-1
• Molecular Weight: 194.274
• Mol File: 22157-91-1.mol

Chemical Properties

• CAS DataBase Reference: 1,3-bis(hydroxymethyl)-5-tert-butylbenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-bis(hydroxymethyl)-5-tert-butylbenzene(22157-91-1)
• EPA Substance Registry System: 1,3-bis(hydroxymethyl)-5-tert-butylbenzene(22157-91-1)

Safety Data

• Hazardous Substances Data: 22157-91-1(Hazardous Substances Data)

Upstream product

• 2359-09-3 5-t-butylisophthalic acid 
• 108-38-3 m-xylene 
• 98-19-1 5-tert-Butyl-m-xylene 
• 16308-65-9 dimethyl 5-(tert-butyl)isophthalate 

Downstream Products

• 216976-23-7 1,3-bis(5-bromo-3-t-butylsalicyl)-5-t-butylbenzene 
• 1454305-86-2 1-tert-butyl-3,5-di(prop-2-yn-1-yl)benzene 
• 156783-43-6 3-tert-butyl-1,5-bis((dimethylamino)methyl)benzene 
• 1454305-95-3 C₂₂H₃₄Si₂ 
• 64726-28-9 5-tert-butyl-1,3-bis(bromomethyl)benzene 
• 339064-30-1 4-amino-3,5-bis[[[3-tert-butyl-5-(4,5-dibutylimidazolyl)methyl]phenyl]methyl]-1,2,4-triazole 
• 339064-34-5 3,5-bis[[[3-tert-butyl-5-(4,5-dibutylimidazolyl)methyl]phenyl]methyl]-1,2,4-triazole 
• 339064-29-8 4-amino-3,5-bis[[3-tert-butyl-5-(imidazolylmethyl)phenyl]methyl]-1,2,4-triazole 
• 339064-33-4 3,5-bis[[3-tert-butyl-5-(imidazolylmethyl)phenyl]methyl]-1,2,4-triazole 
• 339064-27-6 [3-tert-butyl-5-[(4,5-dibutylimidazolyl)methyl]phenyl]acetonitrile 
• 339064-22-1 [3-tert-butyl-5-[(4,5-dibutylimidazolyl)methyl]phenyl]methanol 
• 339064-26-5 [3-tert-butyl-5-(imidazolylmethyl)phenyl]acetonitrile 
• 339064-21-0 [3-tert-butyl-5-(imidazolylmethyl)phenyl]methanol 
• 339064-19-6 [3-tert-butyl-5-(chloromethyl)phenyl]methanol 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS

Compounds and methods for use to treat a bacterial infection caused by, for example, gram positive bacteria, gram negative bacteria, and/or mycobacteria are provided herein. Also provided herein are compounds and methods for use in potentiating the effect of an antibiotic in the treatment of a bacterial infection. Pharmaceutical compositions including the compounds as described herein are also provided.

Examination of the Dynamic Covalent Chemistry of [2 + 3]-Imine Cages

The synthesis of shape-persistent organic cage compounds by the formation of imine bonds opens the possibility to realize cages of different sizes, geometries, topologies, and functions. It is generally assumed that the imine bond is rather chemically labile allowing a self-correction mechanism until thermodynamic equilibrium is reached, which is often the case if a cage is formed. However, there are some contradictory experimental data to this assumption. To get a deeper insight into the imine bond dynamics of covalent organic cages, we studied the formation and exchange of both dialdehydes and triamines of two different [2 + 3] imine cages with the aid of a deuterated dialdehyde molecular building block.

AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS

Compounds and methods for the treatment of a bacterial infection or the potentiation of an antibiotic in treating a bacterial infection are described herein.

Synthesis and conformational analysis of 2,11-dioxa[3.3]metacyclophanes

Synthesis and conformational analysis of three members of the dioxa[3.3]metacyclophane family were carried out. Variable-temperature 1H NMR spectroscopy was employed to show that three substances exist as equilibrium mixtures of syn and anti conformers in ratios that depend on the nature of arene ring substituent, temperature, and solvent. The findings are explained in terms of thermodynamic parameters and dipole moments of the metacyclophanes.

ZINC COMPLEX

A zinc complex characterized in exhibiting an octahedral structure and being configured from repeating units represented by general formula (I): wherein L represents a linker region, and R1 represents a C1-4 alkyl group, which can have a halogen atom.

C3-Symmetric chiral trisimidazoline: The role of a third imidazoline and its application to the nitro Michael reaction and the α-amination of β-ketoesters

We describe the necessity of the C3-symmetry and the role of a third imidazoline of trisimidazoline 3, which was recently developed by us as a new entry of organocatalyst. The utility of 3 as a Br?nsted base catalyst in the nitro Michael reaction and the α-amination of β-ketoesters was shown, and the recyclability of the catalyst was also demonstrated.

A rapid microwave-assisted procedure for easy access to Npolydentate ligands for potential application in α-RIT

Heterocycles bearing a hydrazine moiety react with bisaldehydes or bisketones to afford new Npolydentate ligands suitable for -radioimmunotherapy. We developed a fast and efficient method using microwave-assisted technology to obtain chelators with variab

Hexameric palladium(II) terpyridyl metallomacrocycles: Assembly with 4,4′-bipyridine and characterization by TWIM mass spectrometry

TWIM peaks: A macrocycle containing 12 PdII terpyridyl centers was assembled using 4,4′-bipyridyl ligands and characterized by NMR and traveling wave ion mobility mass spectrometry (TWIM-MS). The macrocyclic architecture was also examined by tandem mass s

Trienoic retinoid compounds and methods

Novel trienoic compounds having activity for retinoic acid receptors and retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such compounds and methods for their use.

Synthesis and characterization of a highly potent and selective isotopically labeled retinoic acid receptor ligand, ALRT1550

The syntheses of two labeled homologues of (2E,4E,6E)-7-(3,5-di-tert- butylphenyl)-3-methylocta-2,4,6-trienoic acid (ALRT1550, 2), [13CD3]ALRT1550 (3) and [3H]ALRT1550 (4), are described in this report. ALRT1550 is an exceptionally potent antiproliferative agent which is currently in phase I/II clinical trials for acute chemotherapy. Both homologues were prepared from commercially available 3,5-di-tert-butylbenzoic acid. Homologue [13CD3]ALRT1550 was labeled at the 7-position of the trienoic acid chain via addition of [13CD3]MgI to a Weinreb amide precursor. The preparation of [3H]ALRT1550 utilized novel methodology to synthesize a sterically hindered and site-specific tritium-labeled tert- butyl group. Saturation binding and Scatchard analysis of this ligand at the retinoic acid receptors are also described, along with competition binding (K(i)) values for a series of known retinoids using [3H]ALRT1550 or [3H]ATRA as the labeled probes.